IN the March issue of this year, a collection of articles on cancer and cytometry (1-3) were published together and highlighted by Editor in Chief, Prof. Attila Tárnok. Our particular focus on those published articles made obvious the fact that flow cytometry continues to play an essential role in the fundamental understanding of cancer progression. The publications had foci that ranged from studies of cancer at a fundamental level to use of mass and imaging cytometry for clinical/therapeutic outcomes. Yet beyond that single issue and our journal as a whole, there exists a massive assemblage of published work (see Fig. 1) that chronicle the salient partnership between cancer and cytometry. Therefore, it is unsurprising that several more articles on the subject of cancer can again be found in the current issue of Cytometry Part A. Hence, we found it not only appropriate to compile a special section related to cancer this month, but also consequential, because of the particular commonality in the research presented. That is, each paper included in our special section demonstrates a new approach for understanding and/or detecting intracellular mechanisms that malfunction during cancer progression-of course, when revealed by flow cytometry.We draw your attention to a group of four original articles on apoptosis and autophagy. These regulatory processes are often studied in cancer cells because they require staged intracellular mechanisms, which if fully understood can be exploited as therapeutic targets. Cytometry as a multiparametric tool has been employed for decades to study these mechanisms (see a few recent publications on these subjects in References 4-8), and the publications we highlight herein exemplify modern approaches toward that end.Four papers in this issue focus on evaluating differences in cells that are either treated with compounds to initiate apoptosis, autophagy, or that circulate in vivo after intravenous injection into anesthetized mice. In the latter case, two articles are featured in which cell counting instruments are designed to detect fluorescence from cells (apoptotic and nonapoptotic) in vivo, as they move through the blood stream after injection. Many of these reports present multiparametric measurements from either in vivo events or from treated cell suspensions, and in doing so demonstrate unique advances to how cytometry can be exploited for diagnosis of cancer or identification of functional traits that occur at the onset of regulated cell death.The paper by Halicka and colleagues (this issue, pp. 683) discusses how multiparametric cytometry (side scatter and fluorescence) is used on apoptosis-induced cells to quantify function of transglutaminase 2 (TG2) and the activation of lysosomal proton pumps as a result of cell treatment by a variety of compounds known to induce DNA damage or cytotoxic outcomes. When detecting the lack of accumulation of acridine orange in compromised lysosomes and protein crosslinking activity of TG2 via scattered light signals, both phenomena can be measure...